Note
9 – Income (loss) per share
Schedule of Income (loss) per share
| | |
Three
months
ended June 30,
2026 | | |
Three
months ended
June 30,
2025 | |
| Net
income (loss) | |
$ | 2,221 | | |
$ | (3,540 | ) |
| Interest
expense related to convertible notes, net of tax | |
| 117 | | |
| — | |
| Loss
on change in fair value of SAFEs | |
| 789 | | |
| — | |
| Gain
on extinguishment of convertible notes and SAFEs, net of tax | |
| (1,916 | ) | |
| — | |
| Fair
value (gain) or loss on embedded derivatives | |
| (2,096 | ) | |
| — | |
| | |
| | | |
| | |
| Diluted
net loss | |
| (885 | ) | |
| (3,540 | ) |
| Weighted average
number of common shares, basic | |
| 912,634 | | |
| 909,366 | |
| SAFEs
notes | |
| 111,648 | | |
| — | |
| Convertible
notes | |
| 165,281 | | |
| — | |
| Dilutive
number of shares | |
| 1,189,563 | | |
| 909,366 | |
| | |
| | | |
| | |
| Basic income (loss)
per share | |
$ | 2.43 | | |
$ | (3.89 | ) |
| Diluted
loss per share (see note below) | |
$ | (0.74 | ) | |
$ | (3.89 | ) |
The
following shares of common stock were excluded from the computation of diluted net income (loss) per share for the periods presented,
as their effect would have been antidilutive:
Schedule of antidilutive
| |
Three
months ended
June 30,
2026 | | |
Three
months ended
June 30,
2025 | |
| Stock options and restricted
stock awards | |
| 128,041 | | |
| — | |
| Convertible
securities | |
| 5,863 | | |
| — | |
| Total | |
| 133,904 | | |
| — | |
Note:
Adjustments for diluted loss per share were not made for the three months ended June 30, 2025, as they would be anti-dilutive
in nature.
|